sickle
The first CRISPR therapy approved in the U.S. will treat sickle cell disease
U.S. patients with sickle cell disease now have a novel treatment option: the first-ever CRISPR-based therapy. On December 8, the U.S. Food and Drug Administration approved the gene-editing therapy for use in patients age 12 years and older. In addition to offering hope of relief for people with severe forms of the painful blood disorder,…